Risperidone half-life in a patient taking paroxetine - A case report

被引：9

作者：

Barnhill, J

Susce, MT

Diaz, FJ

de Leon, J

机构：

[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA

[2] Univ Nacl Medellin, Dept Stat, Medellin, Colombia

来源：

PHARMACOPSYCHIATRY | 2005年 / 38卷 / 05期

关键词：

D O I：

10.1055/s-2005-873159

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This case report further establishes the inhibitory effects of paroxetine on risperidone (R) metabolism in a patient whose R was discontinued due to side effects. Baseline through levels in ng/ml were 33 for R, 9 for 9-hydroxyrisperidone (9-OHR) and 42 for the total moiety. The fourth morning after R discontinuation, levels were 4 for R,1 for 9-OHR and 5 for the total moiety. The estimated half-lives were 23.8 hours for R, 22.8 hours for 9-OHR and 23.5 hours for the total moiety.

引用

收藏

页码：223 / 225

页数：3

相关论文

共 18 条

[1] Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [J].

Agid, O ;

Lerer, B .

JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (01) :55-56

[2] CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline [J].

Alfaro, CL ;

Lam, YWF ;

Simpson, J ;

Ereshefsky, L .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) :155-163

[3] Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors [J].

Balant-Gorgia, AE ;

Gex-Fabry, M ;

Genet, C ;

Balant, LP .

THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :105-115

[4] The AGNP-TDM expert group consensus guidelines:: Therapeutic Drug Monitoring in psychiatry [J].

Baumann, P ;

Hiemke, C ;

Ulrich, S ;

Eckermann, G ;

Gaertner, I ;

Gerlach, M ;

Kuss, HJ ;

Laux, G ;

Müller-Oerlinghausen, B ;

Rao, ML ;

Riederer, P ;

Zernig, G .

PHARMACOPSYCHIATRY, 2004, 37 (06) :243-265

[5] Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients [J].

Berecz, R ;

Llerena, A ;

de la Rubia, A ;

Gómez, J ;

Kellermann, M ;

Dorado, P ;

Degrell, I .

PHARMACOPSYCHIATRY, 2002, 35 (06) :231-234

[6] A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A [J].

Bork, JA ;

Rogers, T ;

Wedlund, PJ ;

de Leon, J .

JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :469-476

[7] Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships [J].

Chou, WH ;

Yan, FX ;

Robbins-Weilert, DK ;

Ryder, TB ;

Liu, WW ;

Perbost, C ;

Fairchild, M ;

de Leon, J ;

Koch, WH ;

Wedlund, PJ .

CLINICAL CHEMISTRY, 2003, 49 (04) :542-551

[8] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation [J].

de Leon, J ;

Susce, MT ;

Pan, RM ;

Fairchild, M ;

Koch, WH ;

Wedlund, PJ .

JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) :15-27

[9]

Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12

[10]

Guzey Cuneyt, 2000, Journal of Clinical Psychiatry, V61, P600